Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov:45:55-66.
doi: 10.1016/j.mam.2015.06.009. Epub 2015 Jul 14.

Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

Mukesh Kumar  1 , Vinicius Ernani  1 , Taofeek K Owonikoko  2
Affiliations
Review

Biomarkers and targeted systemic therapies in advanced non-small cell lung cancer

Mukesh Kumar et al. Mol Aspects Med. 2015 Nov.

Abstract

The last decade has witnessed significant growth in therapeutic options for patients diagnosed with lung cancer. This is due in major part to our improved technological ability to interrogate the genomics of cancer cells, which has enabled the development of biologically rational anticancer agents. The recognition that lung cancer is not a single disease entity dates back many decades to the histological subclassification of malignant neoplasms of the lung into subcategories of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). While SCLC continues to be regarded as a single histologic and therapeutic category, the NSCLC subset has undergone additional subcategorizations with distinct management algorithms for specific histologic and molecular subtypes. The defining characteristics of these NSCLC subtypes have evolved into important tools for prognosis and for predicting the likelihood of benefit when patients are treated with anticancer agents.

Keywords: ALK; Biomarkers; EGFR; Lung cancer; NSCLC; RET; ROS1.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanisms of resistance to ALK inhibitor therapy reported in published data generated from tumor samples obtained from patients with acquired resistance to crizotinib (74, 78, 84)
See this image and copyright information in PMC

References

    1. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clinical pharmacology and therapeutics. 2001;69(3):89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed
    1. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. European journal of cancer. 2008;44(7):946–53. doi: 10.1016/j.ejca.2008.03.006. - DOI - PubMed
    1. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y. The new World Health Organization classification of lung tumours. The European respiratory journal. 2001;18(6):1059–68. - PubMed
    1. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6(2):244–85. doi: 10.1097/JTO.0b013e318206a221. - DOI - PMC - PubMed
    1. Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12):1468–81. doi: 10.1097/JTO.0b013e318189f551. - DOI - PubMed

MeSH terms